Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: A report from the Taiwan Pediatric Oncology Group

Leukemia

Volumn 13, Issue 2, 1999, Pages 155-160

  Liang, D C ^c   Hung, I J ^a   Yang, C P ^a   Lin, K H ^d   Chen, J S ^d   Hsiao, T C ^a   Chang, T T ^d   Pui, C H ^b   Lee, C H ^d   Lin, K S ^d  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NONE

Author keywords

Acute lymphoblastic leukemia; L asparaginase; Remission induction

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLEEDING; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; IMMUNOPHENOTYPING; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL DRUG ADMINISTRATION; PERIANAL ABSCESS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; TAIWAN;

EID: 0033000574     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401260     Document Type: Article

References (22)

1. Pui C-H. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
2. Lin S-T, Liang D-C, Hung I-J, Yang C-Y, Yang Y-M, Chen H-N, Hsieh Y-L, Lin C-Y, Lin M-T, Twu B-H, Law K-L, Tsai Y-M, Lin K-H, Peng C-T, Chen C-H, Chen P-M. Treatment of childhood acute lymphoblastic leukemia with protocol TCL 821 : a report of Taiwan Children's Cancer Study Group. J Formos Med Assoc 1989; 88: 48-56.
3. Yang C-P, Lin S-T, Liang D-C, Hung I-J, Yang Y-M, Chen H-N, Hsieh Y-L, Law K-L, Lin M-T, Twu B-H, Lin K-H, Tsai Y-M, Peng C-T, Chen P-M. Treatment of childhood acute lymphoblastic leukemia with protocol TCL-842 in Taiwan: The Taiwan Children's Cancer Study Group. J Formos Med Assoc 1993; 92: 431-439.
4. Lin K-H, Chen J-S, Hung I-J, Yang C-P, Jaing T-H, Lin D-T, Chen R-L, Jou S-T, Liang D-C, Chen S-H, Chang T-T, Chiou S-S, Hsieh Y-L, Chang T-K, Lin M-T, Hsiao T-C, Peng C-T, Wang C-C, Cheng S-N, Ong C-W, Chen B-W, Lin S-T, Chen H-N, Chen W-D, Lin K-S. Seven year experience of childhood acute lymphoblastic leukemia - a report from Taiwan Pediatric Oncology Group (TPOG). Med Pediatr Oncol 1995; 25: 294 (Abstr. P-63).
5. Liang D-C. TPOG-ALL-93-SR (standard risk). In: Greaves L, Elphinstone T, Sinclair D (eds). International Register of Current Randomised Trials in Childhood Acute Lymphoblastic Leukemia. Clinical Trial Service Unit: Oxford, UK, 1996, p 53.
6. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
7. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
8. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady R, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med 1986; 315: 657-663.
9. Liang D-C, Ma S-W. A simple and rapid in situ staining method for granulocyte-macrophage colonies in agar culture. Int J Cell Cloning 1988; 6: 25-29.
10. Chuu W-M, Tien H-F, Lin D-T, Lin K-H, Su I-J, Chen B-W, Lin K-S, Liang D-C. Infant leukemia: an analysis of nine Chinese patients. Am J Hematol 1990; 34: 246-251.
11. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, Ribeiro RC, Sandlund JT, Crist WM, Pui C-H. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. New Engl J Med 1993; 329: 314-319.
12. Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman GA, Rail TW, Nies AS, Taylor P (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics, edn 8. Pergamon: New York, 1991, pp 1209-1263.
13. Stewart CF, Fleming RA, Arbuck SG, Evans WE. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 1990; 50: 6854-6856.
14. Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui C-H, Rivera GK. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. J. Pharmacol Exp Ther 1992; 260: 71-77.
15. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-358.
16. Nesbit ME, Ertel I, Hammond GD. L-asparaginase as a single agent in acute lymphoblastic leukemia: survey of Children Cancer Study Group. Cancer Treat Rep 1981; 65 (Suppl. 4): 101-107.
17. Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, Verspohl EJ, Ritter J, Jurgens H. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32: 1544-1550.
18. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, Jurgens H, Boos J. Dose reduction of asparaginase: under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol 1997; 96: 675-681.
19. Boos J. Pharmacokinetic and drug monitoring of L-asparaginase treatment. Int J Clin Pharmacol Therapeut 1997; 35: 946-965.
20. Nowak-Gottl U, Ahlke E, Klosel K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukemia re-induction therapy using three different asparaginase preparations. Eur J Paediatr 1997; 35: 96-98.
21. Sutor AH, Niemeyer C, Sauter S, Witt I, Kaufmehl K, Romback A, Brandis M, Riehm H. Gerinnungs veranderungen bei Behandlung mit den Protokollen ALL-BFM-90 und NHL-BFM-90. Klin Padiatrie 1992; 204: 264-273.
22. Otten J, Suciu S, Lutz P, Benoit Y, Robert A, Thyss A, Plouvier E, Ferster A, Mechiwaud F, Mazingue F, Brock P, Vilmer E, Solbu G, Waterkeyn C, Philippe N. The importance of L-asparaginase (A'ASE) in the treatment of acute lymphoblastic leukemia in children: results of the EORTC 58881 randomized phase trial showing greater efficiency of Escherichia coli as compared to Erwinia A'ASE. Blood 1996; 88 (Suppl. 1): 669 (Abstr. 2663).